[{"id":"17d5dfd7-684d-4f90-850e-e14953c32f5a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04091867","created_at":"2021-01-18T20:01:30.016Z","updated_at":"2025-02-25T12:37:25.866Z","phase":"Phase 1","brief_title":"sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC","source_id_and_acronym":"NCT04091867","lead_sponsor":"University of Colorado, Denver","biomarkers":" EPHB4","pipe":" | ","alterations":" EGFR expression • CDKN2A negative","tags":["EPHB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cisplatin • carboplatin • sEphB4-HSA"],"overall_status":"Completed","enrollment":" Enrollment 3","initiation":"Initiation: 01/06/2020","start_date":" 01/06/2020","primary_txt":" Primary completion: 05/14/2021","primary_completion_date":" 05/14/2021","study_txt":" Completion: 10/25/2022","study_completion_date":" 10/25/2022","last_update_posted":"2025-02-24"},{"id":"f99d43e2-a88e-46e7-9ba6-67aaeb1cdec6","acronym":"RTOG 1216","url":"https://clinicaltrials.gov/study/NCT01810913","created_at":"2021-01-18T08:01:55.190Z","updated_at":"2025-02-25T13:52:01.448Z","phase":"Phase 2/3","brief_title":"Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer","source_id_and_acronym":"NCT01810913 - RTOG 1216","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • CD4","pipe":" | ","alterations":" CDKN2A negative","tags":["EGFR • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cisplatin • Tecentriq (atezolizumab) • docetaxel • Datalai (cetuximab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 613","initiation":"Initiation: 03/22/2013","start_date":" 03/22/2013","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2025-02-20"},{"id":"f50a6954-425a-469c-884c-d216b112249b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04966481","created_at":"2021-07-19T14:52:29.062Z","updated_at":"2025-02-25T17:37:14.294Z","phase":"Phase 3","brief_title":"Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor","source_id_and_acronym":"NCT04966481","lead_sponsor":"Washington University School of Medicine","biomarkers":" CDKN2A","pipe":" | ","alterations":" CDKN2A negative","tags":["CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Ibrance (palbociclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 04/06/2022","start_date":" 04/06/2022","primary_txt":" Primary completion: 02/28/2027","primary_completion_date":" 02/28/2027","study_txt":" Completion: 02/28/2027","study_completion_date":" 02/28/2027","last_update_posted":"2025-01-29"},{"id":"939d1cf5-27ac-48f1-9f3d-96f6a19b535a","acronym":"NRG-HN008","url":"https://clinicaltrials.gov/study/NCT04533750","created_at":"2021-01-29T07:21:21.551Z","updated_at":"2024-07-02T16:34:37.751Z","phase":"Phase 1","brief_title":"Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin","source_id_and_acronym":"NCT04533750 - NRG-HN008","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" CDKN2A negative","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • peposertib (M3814)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 12/20/2021","start_date":" 12/20/2021","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2024-06-06"},{"id":"96e48296-f381-4772-98f3-07a1e8a41503","acronym":"KEYNOTE-E40","url":"https://clinicaltrials.gov/study/NCT05280314","created_at":"2022-03-15T18:52:56.379Z","updated_at":"2025-02-25T16:17:24.858Z","phase":"Phase 2","brief_title":"Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors","source_id_and_acronym":"NCT05280314 - KEYNOTE-E40","lead_sponsor":"IO Biotech","biomarkers":" CD4","pipe":" | ","alterations":" CDKN2A negative","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Cylembio (imsapepimut and etimupepimut, adjuvanted)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 12/21/2023","start_date":" 12/21/2023","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-03-18"},{"id":"79fc19fa-8e81-4240-8411-e1af2a9cdd37","acronym":"","url":"https://clinicaltrials.gov/study/NCT06084845","created_at":"2023-10-16T15:12:57.739Z","updated_at":"2024-07-02T16:35:14.380Z","phase":"Phase 2","brief_title":"Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer","source_id_and_acronym":"NCT06084845","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" TNFA","pipe":" | ","alterations":" CDKN2A negative","tags":["TNFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • xevinapant (Debio 1143)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 04/12/2024","start_date":" 04/12/2024","primary_txt":" Primary completion: 05/31/2028","primary_completion_date":" 05/31/2028","study_txt":" Completion: 05/31/2028","study_completion_date":" 05/31/2028","last_update_posted":"2024-03-15"},{"id":"1298df82-fea9-4c88-a556-16ea26ba5ee0","acronym":"KEYNOTE-412","url":"https://clinicaltrials.gov/study/NCT03040999","created_at":"2021-01-18T14:58:21.939Z","updated_at":"2024-07-02T16:35:17.739Z","phase":"Phase 3","brief_title":"Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)","source_id_and_acronym":"NCT03040999 - KEYNOTE-412","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" PD-L1","pipe":" | ","alterations":" CDKN2A negative","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 804","initiation":"Initiation: 04/05/2017","start_date":" 04/05/2017","primary_txt":" Primary completion: 05/31/2022","primary_completion_date":" 05/31/2022","study_txt":" Completion: 08/16/2024","study_completion_date":" 08/16/2024","last_update_posted":"2024-02-26"},{"id":"ec615f4d-a1f5-420c-8706-37dab56e2c0b","acronym":"Los Tres Paso","url":"https://clinicaltrials.gov/study/NCT03389477","created_at":"2021-01-18T16:43:43.069Z","updated_at":"2024-07-02T16:35:19.642Z","phase":"Phase 2","brief_title":"Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT03389477 - Los Tres Paso","lead_sponsor":"Washington University School of Medicine","biomarkers":" CDKN2A","pipe":" | ","alterations":" CDKN2A negative","tags":["CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cisplatin • Ibrance (palbociclib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 04/27/2018","start_date":" 04/27/2018","primary_txt":" Primary completion: 02/15/2022","primary_completion_date":" 02/15/2022","study_txt":" Completion: 04/06/2027","study_completion_date":" 04/06/2027","last_update_posted":"2024-02-13"},{"id":"862da026-2c68-47b3-8e7b-3572ce0d2d0b","acronym":"NRG-HN009","url":"https://clinicaltrials.gov/study/NCT05050162","created_at":"2021-09-20T14:53:04.461Z","updated_at":"2024-07-02T16:35:20.487Z","phase":"Phase 2/3","brief_title":"Comparing High-Dose Cisplatin Every Three Weeks to Low-Dose Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer","source_id_and_acronym":"NCT05050162 - NRG-HN009","lead_sponsor":"NRG Oncology","biomarkers":" CD4","pipe":" | ","alterations":" CDKN2A negative","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 464","initiation":"Initiation: 10/27/2021","start_date":" 10/27/2021","primary_txt":" Primary completion: 02/09/2031","primary_completion_date":" 02/09/2031","study_txt":" Completion: 02/09/2036","study_completion_date":" 02/09/2036","last_update_posted":"2024-02-07"},{"id":"8682504b-572b-4737-8439-d7419d3d16de","acronym":"TIRACAN","url":"https://clinicaltrials.gov/study/NCT05483400","created_at":"2022-08-02T13:55:14.215Z","updated_at":"2024-07-02T16:35:23.652Z","phase":"Phase 2","brief_title":"Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors","source_id_and_acronym":"NCT05483400 - TIRACAN","lead_sponsor":"University Medical Center Groningen","biomarkers":" CD8","pipe":" | ","alterations":" CDKN2A negative","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • tiragolumab (RG6058)"],"overall_status":"Recruiting","enrollment":" Enrollment 97","initiation":"Initiation: 10/18/2023","start_date":" 10/18/2023","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-01-12"},{"id":"f99bffc5-bae9-410e-88dc-0278c7acb439","acronym":"","url":"https://clinicaltrials.gov/study/NCT05743270","created_at":"2023-02-24T16:01:22.500Z","updated_at":"2025-02-25T14:17:41.520Z","phase":"Phase 2","brief_title":"Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN","source_id_and_acronym":"NCT05743270","lead_sponsor":"Replimune Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" CDKN2A negative","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • carboplatin • paclitaxel • RP3"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/30/2024","start_date":" 01/30/2024","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2023-12-29"},{"id":"a140800b-3cce-4ffb-b56e-111439542768","acronym":"TRYHARD","url":"https://clinicaltrials.gov/study/NCT01711658","created_at":"2021-01-18T07:27:31.429Z","updated_at":"2025-02-25T13:18:00.322Z","phase":"Phase 2","brief_title":"TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.","source_id_and_acronym":"NCT01711658 - TRYHARD","lead_sponsor":"Radiation Therapy Oncology Group","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" CDKN2A negative","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • lapatinib"],"overall_status":"Completed","enrollment":" Enrollment 142","initiation":"Initiation: 03/15/2013","start_date":" 03/15/2013","primary_txt":" Primary completion: 12/01/2020","primary_completion_date":" 12/01/2020","study_txt":" Completion: 09/21/2022","study_completion_date":" 09/21/2022","last_update_posted":"2023-10-17"},{"id":"c74875d8-9130-49eb-b214-6853f919bb75","acronym":"PALATINUS","url":"https://clinicaltrials.gov/study/NCT02499120","created_at":"2021-01-18T12:03:10.689Z","updated_at":"2024-07-02T16:35:37.685Z","phase":"Phase 2","brief_title":"Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer","source_id_and_acronym":"NCT02499120 - PALATINUS","lead_sponsor":"Pfizer","biomarkers":" RB1","pipe":" | ","alterations":" CDKN2A negative • RB1 positive","tags":["RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A negative • RB1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Ibrance (palbociclib)"],"overall_status":"Completed","enrollment":" Enrollment 125","initiation":"Initiation: 09/10/2015","start_date":" 09/10/2015","primary_txt":" Primary completion: 07/19/2018","primary_completion_date":" 07/19/2018","study_txt":" Completion: 09/07/2022","study_completion_date":" 09/07/2022","last_update_posted":"2023-09-08"},{"id":"5bec0696-6933-431c-a87d-bd8f954d4389","acronym":"","url":"https://clinicaltrials.gov/study/NCT06022276","created_at":"2023-09-01T17:11:46.994Z","updated_at":"2024-07-02T16:35:38.278Z","phase":"","brief_title":"Nimotuzumab for EGFR-amplified Advanced Pan Solid Tumors","source_id_and_acronym":"NCT06022276","lead_sponsor":"Tianjin Medical University Second Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR amplification • CDKN2A negative","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TheraCIM (nimotuzumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 12/01/2022","start_date":" 12/01/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-09-01"},{"id":"8c883323-31c3-4d97-b8db-606dd9dbea3e","acronym":"IMSTAR-HN","url":"https://clinicaltrials.gov/study/NCT03700905","created_at":"2021-01-18T18:08:16.282Z","updated_at":"2024-07-02T16:35:47.357Z","phase":"Phase 3","brief_title":"Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy","source_id_and_acronym":"NCT03700905 - IMSTAR-HN","lead_sponsor":"Universitätsklinikum Hamburg-Eppendorf","biomarkers":" PD-L1","pipe":" | ","alterations":" CDKN2A negative","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 276","initiation":"Initiation: 08/21/2018","start_date":" 08/21/2018","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2023-05-23"},{"id":"8d398c94-f489-4992-bf96-94394303f9e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03162731","created_at":"2021-01-18T15:35:42.208Z","updated_at":"2025-02-25T14:26:23.274Z","phase":"Phase 1","brief_title":"Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck Cancer","source_id_and_acronym":"NCT03162731","lead_sponsor":"Sidney Kimmel Cancer Center at Thomas Jefferson University","biomarkers":" PD-L1","pipe":" | ","alterations":" CDKN2A negative","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 05/11/2017","start_date":" 05/11/2017","primary_txt":" Primary completion: 09/27/2020","primary_completion_date":" 09/27/2020","study_txt":" Completion: 11/16/2022","study_completion_date":" 11/16/2022","last_update_posted":"2022-11-17"},{"id":"e482ca32-cb06-481e-8b1d-e75fa0180f37","acronym":"","url":"https://clinicaltrials.gov/study/NCT04831450","created_at":"2021-04-05T12:52:49.415Z","updated_at":"2024-07-02T16:36:06.099Z","phase":"Phase 2","brief_title":"Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)","source_id_and_acronym":"NCT04831450","lead_sponsor":"University of Miami","biomarkers":" PD-L1","pipe":" | ","alterations":" CDKN2A negative","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Libtayo (cemiplimab-rwlc)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/01/2022","start_date":" 07/01/2022","primary_txt":" Primary completion: 07/15/2022","primary_completion_date":" 07/15/2022","study_txt":" Completion: 07/15/2022","study_completion_date":" 07/15/2022","last_update_posted":"2022-08-04"},{"id":"0f520337-0cec-472e-b063-27456f36d835","acronym":"","url":"https://clinicaltrials.gov/study/NCT05351762","created_at":"2022-04-28T16:57:05.400Z","updated_at":"2024-07-02T16:36:07.840Z","phase":"Phase 2","brief_title":"Nimotuzumab Combined With Neoadjuvant Chemotherapy in the Treatment of Resectable LA HNSCC","source_id_and_acronym":"NCT05351762","lead_sponsor":"Xijing Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression • EGFR positive • CDKN2A negative","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • EGFR positive • CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • Aqupla (nedaplatin) • TheraCIM (nimotuzumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 07/01/2022","start_date":" 07/01/2022","primary_txt":" Primary completion: 05/30/2024","primary_completion_date":" 05/30/2024","study_txt":" Completion: 07/30/2024","study_completion_date":" 07/30/2024","last_update_posted":"2022-07-04"},{"id":"dbf8656b-36f6-4dfd-b40c-017f2c246807","acronym":"NRG-HN003","url":"https://clinicaltrials.gov/study/NCT02775812","created_at":"2021-01-18T13:36:43.056Z","updated_at":"2024-07-02T16:36:09.071Z","phase":"Phase 1","brief_title":"Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT02775812 - NRG-HN003","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":" | ","alterations":" CDKN2A negative","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 11/28/2016","start_date":" 11/28/2016","primary_txt":" Primary completion: 12/03/2018","primary_completion_date":" 12/03/2018","study_txt":" Completion: 05/20/2022","study_completion_date":" 05/20/2022","last_update_posted":"2022-06-10"},{"id":"2ea36251-0a37-4f01-ac02-6a770fb828cb","acronym":"","url":"https://clinicaltrials.gov/study/NCT03292250","created_at":"2021-01-18T16:15:56.076Z","updated_at":"2024-07-02T16:36:14.544Z","phase":"Phase 2","brief_title":"Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]","source_id_and_acronym":"NCT03292250","lead_sponsor":"Seoul National University Hospital","biomarkers":" HER-2 • FGFR","pipe":" | ","alterations":" CDKN2A negative","tags":["HER-2 • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Piqray (alpelisib) • Verzenio (abemaciclib) • Imjudo (tremelimumab-actl) • nintedanib • Pozenveo (poziotinib)"],"overall_status":"Completed","enrollment":" Enrollment 180","initiation":"Initiation: 09/10/2017","start_date":" 09/10/2017","primary_txt":" Primary completion: 03/01/2020","primary_completion_date":" 03/01/2020","study_txt":" Completion: 03/10/2022","study_completion_date":" 03/10/2022","last_update_posted":"2022-03-29"},{"id":"4af71c00-ace8-4969-94d5-7875335d00f9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05024019","created_at":"2021-08-27T13:53:06.956Z","updated_at":"2024-07-02T16:36:25.746Z","phase":"Phase 2","brief_title":"Nimotuzumab Combined With Radiotherapy in High-risk Patients With HNSCC Not Suitable for Cisplatin After Surgery","source_id_and_acronym":"NCT05024019","lead_sponsor":"Eye \u0026 ENT Hospital of Fudan University","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression • CDKN2A negative","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • TheraCIM (nimotuzumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 08/21/2021","start_date":" 08/21/2021","primary_txt":" Primary completion: 08/21/2025","primary_completion_date":" 08/21/2025","study_txt":" Completion: 08/21/2025","study_completion_date":" 08/21/2025","last_update_posted":"2021-08-27"},{"id":"c8ff45fc-0318-40cc-8ebd-bc96f5654bdd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04411121","created_at":"2021-01-18T21:16:05.423Z","updated_at":"2024-07-02T16:36:43.820Z","phase":"Phase 2/3","brief_title":"Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-risk Head and Neck Cancer","source_id_and_acronym":"NCT04411121","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • CD4","pipe":" | ","alterations":" CDKN2A negative","tags":["EGFR • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cisplatin • Tecentriq (atezolizumab) • docetaxel • Datalai (cetuximab biosimilar)"],"overall_status":"Suspended","enrollment":" Enrollment 613","initiation":"Initiation: 03/18/2013","start_date":" 03/18/2013","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":"","study_completion_date":"","last_update_posted":"2020-06-25"},{"id":"1c6efed5-6fce-43e0-976e-7a67e62c7ecd","acronym":"","url":"https://clinicaltrials.gov/study/NCT00339404","created_at":"2021-01-18T01:10:24.604Z","updated_at":"2024-07-02T16:37:20.363Z","phase":"","brief_title":"Genetic Analysis of Familial Melanoma","source_id_and_acronym":"NCT00339404","lead_sponsor":"National Human Genome Research Institute (NHGRI)","biomarkers":" CDKN2A • CDK4","pipe":" | ","alterations":" CDKN2A negative • CDK4 mutation","tags":["CDKN2A • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A negative • CDK4 mutation"],"overall_status":"Completed","enrollment":" Enrollment 3000","initiation":"Initiation: 03/04/1999","start_date":" 03/04/1999","primary_txt":"","primary_completion_date":"","study_txt":" Completion: 03/07/2011","study_completion_date":" 03/07/2011","last_update_posted":"2017-07-02"}]